Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression

Completed · Phase 4

Conditions studied: Depression

In brief

This study will determine the effectiveness of desipramine in improving cellular signaling, and thereby decreasing symptoms of depression in people with major depressive disorder (MDD).

Key facts

Study ID

NCT00320632

Run by

Harvard Medical School (HMS and HSDM)

People needed

43

Starts

1990-08-01

Expected to finish

1993-07-01

Last updated by the study team

2015-08-19

Who can join

Age: 19 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Clinical diagnosis of MDD (as defined by SCID [DSM III-R] and a score of at least 15 on the 21-item Hamilton Depression Scale)
• Able to swallow tablets, give urine and blood samples, and participate in periodic evaluations during the study
• Healthy volunteers show no current Axis I or Axis II disorders and score less than 8 on the Hamilton Depression Scale

You may not qualify if…

• Use of any of the following medications within the 2 weeks prior to study entry: psychoactive medication; aspirin; or nonsteroidal anti-inflammatory agents
• Any alcohol or drug abuse within the 6 months prior to study entry
• Any major medical disorder

Where it is running

• Massachusetts Mental Health Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.